When it comes to an effective aromatase inhibitor, the mention of Cytadren comes at the first place.
Cytadren, which is also known as Aminoglutethimide, is an effective inhibitor of desmolase (an enzyme required for steroid production in the body). This drug is considered to be exemplary when use of aromatizable steroids is the basic intention of steroid users.
In the world of bodybuilding, Cytadren is an effective antiestrogen especially in the stage of post cycle therapy. Since this drug can easily inhibit the conversion of cholesterol to pregnenolone, it is admired by bodybuilders when it comes to reducing or eliminating the formation of estrogens.
It is considered to be second to none while a sportsman or bodybuilder is dieting for a contest. The characteristics of this drug are of great worth when the circulating androgens get totally replaced by synthetic androgens during dieting and before the contest. This is an effective antiestrogen for all those sportsmen who want to stay away from the possible side effects of harsh steroids or aromatizable steroids that could have led to side effects such as gynecomastia and fluid retention.
In addition to all these benefits, Cytadren is also useful because of its unique anti-depressive properties.
Recommended Dose
The recommended dose of Cytadren is 100-200 mg/day, with or without meals. The use of Cytadren must be recommended by a qualified medical practitioner else a situation of substance abuse is not far away.
We hope that this information on Cytadren, the effective aromatase inhibitor, helped you to gain a clear and complete insight on this miracle drug.
When it comes to treating a common viral lower respiratory infection in infants, bronchiolitis, steroid medications are not effective in terms of ensuring improvements in the level of respiratory symptoms or preventing hospitalization.
The finding was revealed by the Pediatric Emergency Care Applied Research Network (PECARN) and appeared in an issue of The New England Journal of Medicine.
“This study provides solid evidence to guide treatment of this common illness,” said Joseph Zorc, M.D., an emergency physician at The Children’s Hospital of Philadelphia (CHOP) and a lead co-investigator. “Current recommendations suggest that simple supportive care is the best available treatment for bronchiolitis. This study will help resolve some of the uncertainty for physicians and families and prevent unnecessary side effects.”
Both physicians note that glucocorticoid medications still play an important role in other respiratory illnesses of childhood such as asthma and croup. They point out these medications are not the androgenic steroids sometimes abused by athletes, and that the side effects seen with long-term steroid use are not a risk in the short-course treatments used for croup and asthma attacks.
Nathan Kuppermann, M.D., a professor of emergency medicine and pediatrics at the University of California, Davis, chair of the PECARN network’s steering committee, and the senior investigator of the study, said that the authority of a research network like PECARN is highlighted and reaffirmed when it comes to resolving the difficult-to-answer questions.
When it comes to hiding your success secret (steroid use) during doping tests, diuretics are exemplary drugs. Let us read about them to gain a clear and complete understanding.
Diuretics are prescription or over-the-counter drug products such as bumetanide (Bumex) and furosemide (Lasix) that augment diuresis or fluid removal from the body via urination. They are commonly used by steroid users before the start of a competitive event for gaining advantages over their peers. The fact that use of steroids and performance enhancing drugs can be kept hidden with the use of diuretics is something that is admired by sportsmen, especially bodybuilders and strength athletes.
In addition to enhancing performance, diuretics are also used for losing excess body weight without any troubles. Easy and safe to use, diuretics can be used by any one but only after a round of consultation with a qualified healthcare professional. It is important to note here that use of low-grade or abuse of diuretics can lead to potential side effects such as potassium deficiency and dehydration.
In the world of medicines, diuretics are also used to treat people suffering from edema and high blood pressure. This is done by stimulating an increase in the urine production for fluid release and getting rid of excess body salts besides reduction of blood volume.
Availability of Diuretics
Diuretics are usually available in an injectable form but one can find natural diuretics in the form of apple cider vinegar, beverages containing caffeine, and cranberry juice to name a few.
A new autoinflammatory syndrome was recently discovered by researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, and other institutions.
The syndrome was named as DIRA (deficiency of the interleukin-1 receptor antagonist) and can be termed as a rare genetic condition affecting children around the time of birth.
The scientists identified nine patients from six families with DIRA in the Canadian province of Newfoundland, the Netherlands, Lebanon, and Puerto Rico. Those who were alive at the time of diagnosis – six in all – were treated with anakinra, a drug that is normally used for rheumatoid arthritis and is a synthetic form of human IL-1Ra. Although the patients were resistant to other medications such as steroids, most responded successfully and immediately to anakinra. “Our first patient had been unresponsive to several treatments, and his health care team had almost given up. But with anakinra, he was out of the hospital in 10 days and his symptoms resolved,” Dr. Goldbach-Mansky said.
Although the mutation that causes DIRA is rare, as many as 2.5 percent of the population of northwest Puerto Rico are carriers. Since DIRA is recessively inherited, these data suggest that it may be present in about 1 in 6,300 births in this population. Because the mutation was found in three independent Dutch families, newborn screening for DIRA in this population, as well as that of northwest Puerto Rico, may be warranted, Dr. Goldbach-Mansky said.
It was noted that children affected from this syndrome show a constellation of severe symptoms such as bone tissue swelling.
Scientists at the University of Bristol and the National Cancer Institute (NCI), USA have suggested that intermittent signaling by steroid hormones can affect the manner by which genes are expressed in rodents.
The finding is considered to offer considerable implications for understanding how steroids operate and open up novel avenues for new therapies.
In this new study, the researchers demonstrate that ultradian hormone stimulation induces the pulsed expression of genes (known as gene pulsing) over the same period, both in cultured cells and in animal models. Initially, the researchers administered corticosterone, a naturally occurring glucocorticoid hormone in rodents, in a pulsed manner to cultured mouse cells and then observed that the levels of newly synthesized RNA from glucocorticoid receptor-regulated genes tracked precisely with the hormone pulses.
The reported research results argue that gene pulsing regulated by glucocorticoid receptors is directly linked to varying levels of gene activity. Professor Stafford Lightman, head of the Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, at the University of Bristol, said: “We have previously shown that the hormone cortisol is released in pulses in man as well as rodents. The present results now show that this pattern of hormone release is critical for good health and provides a novel concept for new drug design.”
The findings were published online and appeared in the September 2009 issue of Nature Cell Biology.
A protein secreted from adipocytes, Adiponectin, has been found to be the metabolic link between obesity and both bone mineral density (BMD) and reduced susceptibility to fractures.
The finding was revealed during a study by researchers at the University of Toronto, Faculty of Medicine, Toronto, Canada, which appeared in an issue of Experimental Biology and Medicine.
Female mice overexpressing adiponectin had weaker vertebra at 8 weeks of age than control mice and this delay in bone development persisted through to the end of the study period, representing early adulthood. The weaker vertebra model compression fractures of the lumbar spine in humans, among the most common type of fragility fracture associated with low bone mass and osteoporosis. The strength of the femur neck, representing the hip, was also weaker in both females and males overexpressing adiponectin. Serum adiponectin levels were inversely correlated with femur bone mineral content, further emphasizing that a high level of adiponectin impedes bone development at not only the lumbar spine but also the hip. Whether or not the delay in bone development resolves in later life or is sustained and leads to an increased risk of fragility fracture, particularly during aging when bone loss rapidly occurs due to declining levels of sexsteroids, requires further investigation.
The research team, Dr. Michael C. Archer, Earle W. McHenry Professor and Chair, Dr. Wendy E. Ward, Associate Professor, Dr. Kafi Ealey, Postdoctoral Fellow and predoctoral student Jovana Kaludjerovic, in the Department of Nutritional Sciences, evaluated whether or not the diponectin modulates bone development using transgenic mice that overexpress this protein.
In the worlds of performance enhancing drugs, antiestrogens, and steroids, Arimidex is one name that is trusted by one and all especially when steroid cycles involve harsh or aromatizable steroids.
Arimidex, also known as Anastrozole or Liquidex, was initially developed as a drug to treat advanced breast cancer in women. But it slowly gained popularity as a new class of third-generation selective oral aromatase inhibitor. This wonder drug is effective for inhibiting the enzyme aromatase besides inhibiting the production of estrogens, especially after use of harsh or aromatizable drugs during steroid cycles.
It is worth noting here that Arimidex is better than Nolvadex, another antiestrogen, because Arimidex is able to provide improved and dramatic results when compared to Nolvadex.
Even at low doses of 0.25-1.0 mg per day, Arimidex is an exceptional antiestrogen that can inhibit potential risks such as fluid retention and gynecomastia to a great extent. This also means that muscle quality is greater and without any side effects with Arimidex. This oral aromatase inhibitor has an active life of approximately 42-48 hours and can reduce the level of blood pressure when coupled with aromatizable steroids during a steroid cycle.
It is important to note that use of Arimidex should be initiated only after a medical recommendation so that existing allergies to ingredients of Arimidex and possible side effects can be completely ruled out. If this is not taken care of, Arimidex abuse can lead to side effects such as bone pain, peripheral edema, dyspnea, hot flashes, arthritis, insomnia, depression, nausea, and vomiting.
Researchers at the University of Bristol are looking for some volunteers for finding out if hydrocortisone, a drug affecting stress system of the body, can be used to provide relief to people suffering from depression and not responding to present treatments.
Severe or recurrent depression affects 3-5 percent of the population and 10-30 percent of this population falls under the category of patients who do not provide a respond to the available treatment options.
Evidence from UK and US studies suggests that a short course of steroids, such as hydrocortisone, may be sufficient to trigger a beneficial response in people who have TRD who are on ’standard’ antidepressant treatment. If this were to be confirmed, it would be a significant advance as it may enable a restoration of response to conventional treatments in these individuals. A further advantage is that such an intervention is inexpensive, relatively simple and could be carried out in outpatient or even appropriate primary care settings.
The researchers are looking for patients with depression who have failed to respond to two antidepressant medications and who would like to be assessed for entry into the study.
Dr Andrea Malizia leading the team of Bristol researchers has a long-standing clinical and research interest in treatment resistant depression and spearheads a specialist outpatient service at the Bristol Royal Infirmary.
A protein acknowledged for stimulating growth of blood vessels was recently found as the reason behind overgrowth of cells in polyps’ development characterizing one of the most severe forms of sinusitis.
This finding was disclosed during a study by researchers from Johns Hopkins that was aimed at offering a new target for development of new therapies to treat disease form, which typically resists all current treatments.
Kim explains that surgery to remove the polyps is one of the most common treatments for this disease. However, nasal and sinus polyps in these patients almost always regrow. “Once the patient has entered the cycle of growing polyps, it’s very hard to get out,” she says. Another common treatment is oral steroids, but these drugs are fraught with many harmful side effects and also only temporarily treat the disease.
She and her Johns Hopkins colleagues have long studied sinusitis, often growing sinus cells isolated from patients in petri dishes. After noticing that cells from patients with polyps typically multiplied faster than cells from normal patients, the researchers speculated that cells from polyp patients might be producing extra amounts of some type of growth factor, a protein that encourages cell growth.
Jean Kim, M.D., Ph.D., assistant professor in the Departments of Otolaryngology and Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine, and a researcher at the Johns Hopkins Allergy and Asthma Center at the Johns Hopkins Bayview Medical Center, was of the view that this type of sinusitis is not subtle in nature.
During a recent study, it was found that Telithromycin can promote a significant drop in asthma symptoms when used for 10 days.
The drug is presently sold by Sanofi-Aventis under the name Ketek. The involved researchers believe that this drugs’s positive effects can be a result of impact on two bacteria, Chlamydophila pneumoniae and Mycoplasma pneumoniae, which were found in 61 percent of the patients involved in this study.
Asthma is an incurable condition which affects 300 m people worldwide but its symptoms are eased using steroids.
By using a 7-point scale that measured symptoms such as wheezing, coughing and chest tightness with 7 the most severe, most patients rated their symptoms at about 3 before treatment.
Those receiving the drug eventually had their score drop an average of 1.3 points and the placebo recipients had a drop of 1.0 point said the researchers.
Ketek has previously come under scrutiny because it may, in rare cases, cause liver poisoning.
In three such instances reported in January, one patient died, another required a transplant, and the third recovered.
When it comes to an effective aromatase inhibitor, the mention of Cytadren comes at the first place.
When it comes to treating a common viral lower respiratory infection in infants, bronchiolitis, 
When it comes to hiding your success secret (
A new autoinflammatory syndrome was recently discovered by researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the 
Scientists at the 
A protein secreted from adipocytes, Adiponectin, has been found to be the metabolic link between obesity and both bone mineral density (BMD) and reduced susceptibility to fractures.
In the worlds of performance enhancing drugs, antiestrogens, and 
Researchers at the 
A protein acknowledged for stimulating growth of blood vessels was recently found as the reason behind overgrowth of cells in polyps’ development characterizing one of the most severe forms of sinusitis.
During a recent study, it was found that Telithromycin can promote a significant drop in asthma symptoms when used for 10 days.
Recent Comments